Suddenly, groups that rarely agree on anything have started to speak the same language. All of the major medical groups, Trump-aligned politicians, and cannabis industry supporters are applauding a similar development: marijuana moving to Schedule III. It could be. But when institutions with very different motives celebrate the same policy shift, it’s worth slowing down and asking a simple question:
what exactly are they cheering for?
A Rare Moment of Alignment
Earlier this month, the White House set in motion the process of rescheduling cannabis under the Controlled Substances Act. The plant has been listed for decades in Schedule I – a category reserved only for substances that are deemed to be of no medical benefit. (Marijuana was listed alongside heroin and LSD). Now, the plant will land in Schedule III. The Trump administration has directed the Justice Department in writing to expedite the reclassification. Some reports indicate that the change could take place as soon as January 2026. The American Pharmacists Association, or APhA, said that moving cannabis from Schedule II to Schedule III would “accelerate the research into its medical applications” and lead to potentially “safer and effective” therapies. This reaction is logical from a medical perspective. Schedule I restrictions have been a barrier for serious cannabis research for many years. A conservative nonprofit linked to a pro Trump PAC released a new ad that praised the rescheduling as a major win, and explicitly credited Trump for “delivering once again” on cannabis legislation, as
. The ad went so far as to claim that this move will “destroy the cartel’s illicit black market” and help ensure “seniors and veterans receive the care they need.” In other words, the Trump-aligned narrative cast rescheduling as a sweeping, law-and-order win for America.
Different worlds, same development. The story begins there. The Department of Health and Human Services recommended that cannabis be moved to Schedule III. Now, the White House has directed the Attorney General to take steps to complete the process. An executive order was signed to this effect in mid-December. This accelerated a process which began under the previous administration with scientific reviews. Schedule III status would mean:
Official federal recognition of marijuana’s medical use.welcomed the move By definition, Schedule III substances are acknowledged to have accepted medical value.
This is a sharp break from cannabis’s current schedule I status. Schedule III status would mean:reported by Marijuana MomentOfficial federal recognition of marijuana’s medical use.
By definition, Schedule III substances are acknowledged to have accepted medical value, a sharp break from cannabis’s current Schedule I status.
Fewer research barriers.
Rescheduling would ease some of the restrictions researchers faced under Schedule I, making it much simpler to study cannabis in clinical trials, a core argument in the APhA statement.
Potential tax relief for licensed businesses.
- Cannabis companies have been unable to deduct normal business expenses due to IRS Code 280E, a punitive tax rule that applies to Schedule I and II substances. A move to Schedule III would eliminate the 280E tax penalty, potentially saving dispensaries and growers huge sums and improving industry profitability.A symbolic end to cannabis being treated like heroin.
- For over 50 years, federal law has lumped marijuana in the same category as heroin and LSD. This link is broken by rescheduling. It signals that cannabis is no longer deemed among the most dangerous drugs, an important cultural shift even if it’s largely symbolic.Those are real shifts. These changes are not accidental. But they are not the end. What Rescheduling Does and Does Not Do
- This where the message starts to overrun the policy. It’s important to understand what a Schedule III reclassification will not
- accomplish:It does not legalize cannabis at the federal level.
Even if moved to Schedule III, marijuana would remain illegal for general use under federal law. It does not result in expungements, criminal justice reform, or the repair of collateral damage from prohibition. It does not allow interstate commerce. Each state’s market would remain relatively siloed, absent new legislation.
It does not fix the cannabis banking problem.
Major banks and insurers would continue to face legal risks in serving the cannabis industry. The American Bankers Association stated in a press release urging the passage of the SAFER Banking Act that “any potential decision to classify cannabis has no impact on the legal issues surrounding banking it… Cannabis would still be illegal under federal laws, and this is a border many banks will not cross.” It does not dismantle illegal markets. The high tax rates, the limited licenses and state-bystate disparities that have been a driving force behind illicit cannabis sales are all due to rescheduling. None of those issues disappear overnight with a change in federal scheduling.These limitations are structural. These issues require legislative reform or regulatory reforms, and not just a reclassification. Schedule III can be understood as a significant technical change with tangible benefits. It is not an economic or cultural reset. Research is made easier. It could ease the tax burden for businesses that comply. What it does not do is rewrite the rules of the cannabis economy or resolve contradictions in state-by-state legalization. What it does not do is suddenly rewrite the rules of the cannabis economy or resolve the contradictions of state-by-state legalization.Which is exactly why the framing of this moment matters so much.
- Why This Overlap MattersWhen medical associations praise rescheduling, they’re talking about research, safety, and regulation. This is consistent with their roles. The American Association of Nurse Anesthesiology’s
- rescheduling, for example, will increase opportunities for rigorous studies into how cannabinoids and cannabis can relieve pain and how these can interact with anesthesia. Patients and pharmacists also stress that recognition does not equal access. Americans for Safe Access said it clearly: “acknowledgement is not acces,” rescheduling needed but limited. That’s narrative-building. The Trump-linked advertisement wasn’t about science or patient care. The ad was celebrating a victory to energize its supporters and give credit to a politician. It doesn’t matter if both stories are true or not, as long as they revolve around the same policy. But it does mean this single development is being loaded with very different expectations.
- Notably, some of the institutions with the most to gain from true federal legalization, banks, insurers, large financial players, have been far more cautious in their response. The highlights that rescheduling does not resolve the legal grey areas that still exist in the cannabis industry. Patient advocacy groups also welcomed the move, but warned that even after rescheduling patients could still face discrimination and lack of access to cannabis through federal programs. This was noted by the
- . This restraint speaks volumes. Unlike those crafting optimistic press releases, these stakeholders know the job isn’t done until Congress acts or broader legal changes occur.The Real TakeawayABA statement hereRescheduling might (or might not) equal progress. This is long overdue and will likely happen in the near future. It will, in concrete terms remove some of those shackles which have held cannabis research and the industry back. That’s significant.
- But it’s also becoming a kind of political Rorschach test. Medical groups see the path to safer patient care and better science. Politicians can take credit for a victory. Cannabis industry benefits from tax relief, and the move towards normalizing their business. While the cannabis industry is seeing tax relief, the general public hears “legalization” even though it’s not the case. This policy change serves many different narratives, but the truth is hidden between the press release. As always, the devil is in the detail, and these details will emerge in the months and even years following the applause.
